Hepatitis C Virus Infection: Molecular Pathways to Insulin resistance

Virology Journal

Volumn 8, Issue , 2011, Pages

  Parvaiz, Fahed ^a   Manzoor, Sobia ^a   Tariq, Huma ^a   Javed, Farakh ^a   Fatima, Kaneez ^a   Qadri, Ishtiaq ^a  

^a NATIONAL UNIVERSITY OF SCIENCES AND TECHNOLOGY   (Pakistan)

Author keywords

HCV Infection; Insulin Resistance; Molecular Pathways

Indexed keywords

CORE PROTEIN; CYTOKINE; GLUCOSE; GLUCOSE TRANSPORTER 4; INSULIN; INSULIN RECEPTOR SUBSTRATE; INTERLEUKIN 6; INTERLEUKIN 8; LIPID; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5A; PROTEIN KINASE B; TUMOR NECROSIS FACTOR ALPHA; VIRUS PROTEIN;

ARTICLE; CELL ORGANELLE; ENDOPLASMIC RETICULUM; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; GLUCONEOGENESIS; GLUCOSE METABOLISM; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE SYSTEM; INFLAMMATION; INSULIN RESISTANCE; LIPID STORAGE; LIPOGENESIS; MITOCHONDRION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; VIRUS HEPATITIS; ANIMAL; BIOSYNTHESIS; GENETICS; METABOLISM; MOUSE; PATHOPHYSIOLOGY; PHOSPHORYLATION; REVIEW; TRANSGENIC MOUSE; VIROLOGY;

HEPATITIS C VIRUS;

ANIMALS; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION REGULATION; GLUCONEOGENESIS; GLUCOSE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INSULIN; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN RESISTANCE; LIPOGENESIS; MICE; MICE, TRANSGENIC; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; VIRAL NONSTRUCTURAL PROTEINS; VIRAL STRUCTURAL PROTEINS;

EID: 80054107342     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-474     Document Type: Article

References (57)

1. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M, Science 1989 244 359 362 10.1126/science.2523562 2523562 (Pubitemid 19117877)
2. Replication of the hepatitis C virus in cell culture. Bartenschlager R, Kaul A, Sparacio S, Antiviral Res 2003 60 91 102 10.1016/j.antiviral.2003.08.016 14638404 (Pubitemid 37452452)
3. Replication of hepatitis C virus. Bartenschlager R, Lohmann V, J Gen Virol 2000 81 1631 1648 10859368 (Pubitemid 30427068)
4. Hepatitis C virus-inducedoxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Miura K, Taura K, Kodama Y, Schnabl B, Brenner DA, Viral Hepatitis 2008 48 5 1420 1429
5. HCV Induces Oxidative and ER Stress, and Sensitizes Infected Cells to Apoptosis in SCID/Alb-uPA Mice. Joyce MA, Walters KA, Lamb SE, Yeh MM, Zhu LF, Kneteman N, Doyle JS, Katze MG, Tyrrell DL, PLoS Pathog 2009 5 2 1000291 10.1371/journal.ppat.1000291 19242562
6. Hepatitis C Virus Infection: Molecular Pathways to steatosis, Insulin resistance and oxidative stress. Clement S, Pascarella S, Negro F, Virus 2009 1 126 143 10.3390/v1020126
7. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. Micallef JM, Kaldor JM, Dore GJ, J. Viral Hepat 2006 13 1 34 41 10.1111/j.1365-2893.2005.00651.x 16364080
8. Hepatitis C: A Multifaceted Disease Review of Extrahepatic Manifestations. Subhash C, Sanjiv C, Ann Intern med 1995 123 615 620 7677303
9. Worldwide variation in the relative importance of hepatitis B andhepatitis C viruses in hepatocellular carcinoma: a systemic review. Raza SA, Clifford GM, Franceschi B, Br. J.Cancer 2007 96 7 1127 1134 10.1038/sj.bjc. 6603649 17406349 (Pubitemid 46608308)
10. Hepatitis C: the dermatologic profile. Farhana M, Hussain I, Haroon TS, J. Pak.Assoc. Derm 2009 18 171 181
11. A study of best positive predictors for sustained virological response to interferon alpha plus ribavirin therapy in nave hepatitis C patients. Idrees M, Riazuddin S, BMC Gast 2009 9 5
12. Hepatitis C virus infection: A review of the current and future aspects and concerns in Pakistan. Akbar H, Idrees M, Manzoor S, Rehman IU, Butt S, Yousaf MZ, Rafique S, Awan Z, Khubaib B, Akram M, Aftab M, JGMV 2009 1 2 12 18
13. Peginterferon and Ribavirin for Chronic Hepatitis C. Hoofnagle JH, Seeff LB, New Engl J Med 2006 355 2444 51 10.1056/NEJMct061675 17151366 (Pubitemid 44903748)
14. Pathophysiology of insulin resistance. Sesti G, Endocrinology and Metabolism. Best Practice and Research Clinical 2006 20 4 665 679 10.1016/j.beem.2006.09.007 (Pubitemid 44856489)
15. Cellular mechanisms of insulin resistance. Shulman GI, J Clin Invest 2000 106 2 171 176 10.1172/JCI10583 10903330 (Pubitemid 30483118)
16. Quantification of muscle glycogen synthesis in normal subjects and subjects with non-insulin dependent diabetes by C nuclear magnetic resonance spectroscopy. Shulman GI, Rothman DL, Jue T, Stein P, DeFronzo RA, Shulman RG, N Engl J Med 1990 322 4 223 228 10.1056/NEJM199001253220403 2403659 (Pubitemid 20034509)
17. Insulin resistance: A metabolic pathway to chronic liver disease. Bugianesi E, McCullough AJ, Marchesini G, Hepatology 2005 42 987 1000 10.1002/hep.20920 16250043 (Pubitemid 43112663)
18. Insulin resistance, insulin insensitivity, and insulin unresponsiveness: a necessary distinction. Kahn CR, Metabolism 1978 27 1893 1902 10.1016/S0026-0495(78)80007-9 723640 (Pubitemid 9082246)
19. Quantification of the relative impairment in actions of insulin on hepatic glucose production and peripheral glucose uptake in non-insulin- dependent diabetes mellitus. Campbell PJ, Mandarino LJ, Gerich JE, Metabolism 1988 37 15 21 10.1016/0026-0495(88)90023-6 3275857 (Pubitemid 18057190)
20. Insulin resistance impairs sustained response rate to antiviral therapy in patients with chronic hepatitis C. Romero-Gomez M, Corpas R, Grande L, Castellano-Megias VM, Sanchez-Munoz D, del Rocio V, Vazquez-Albertino R, Hepatology 2003 38 747
21. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, Beasley P, Patt YZ, Hepatology 2002 36 1206 1213 10.1053/jhep.2002.36780 12395331 (Pubitemid 35253437)
22. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB, Gut 2005 54 533 539 10.1136/gut.2004.052167 15753540 (Pubitemid 40403031)
23. Insulin Resistance and steatosis in chronic hepatitis C. Machado MV, Cortez-Pinto H, Ann. Hepatol 2009 8 1 67 S75 19381127
24. Chronic hepatitis C and type II diabetes mellitus: a prospective cross-sectional study. Zein CO, Levy C, Basu A, Zein NN, Am J Gastroenterol 2005 100 48 55 10.1111/j.1572-0241.2005.40429.x 15654780 (Pubitemid 41623268)
25. Insulin resistance and hepatitis C. Romero-Gomez M, World J Gastroenterol 2006 12 7075 7080 17131467 (Pubitemid 44890634)
26. Prevalence of diabetes mellitus in Japanese patients infected chronically with hepatitis C virus. Arao M, Murase K, Kusakabe A, Yoshioka K, Fukuzawa Y, Ishikawa T, Tagaya T, Yamanouchi K, Ichimiya H, Sameshima Y, J Gastroenterol 2003 38 355 360 10.1007/s005350300063 12743775 (Pubitemid 36626271)
27. Oxidative stress in the pathogenesis of hepatitis C virus. Choi J, James JH, Mechanisms of liver injury.III, Am J Physiol Gastrointest Liver Physiol 2006 290 847 G851 16603728
28. Gale MJ, Blakely SM, Kwieciszewski B, Tan SL, Dossett M, Tang NM, Korth MJ, Polyak SJ, Gretch DR, Katze MG, Mol. Cell. Biol 1998 18 5208 5218 9710605
29. Involvement of the PA28 Dependent Pathway in Insulin Resistance induced by Hepatitis C Virus Core Protein. Miyamoto H, Moriishi K, Moriya K, Murata S, Tanaka K, Suzuki T, Miyamura T, Koike K, Matsuura Y, J Virol 2007 81 4 1727 1735 10.1128/JVI.01683-06 17135326 (Pubitemid 46214447)
30. Hepatitis C Virus Down-Regulates Insulin Receptor Substrates 1 and 2 through Up-Regulation of Suppressor of Cytokine Signaling 3. Kawaguchi T, Yoshida T, Harada M, Hisamoto T, et al. Gastrointestinal, Hepatobiliary and Pancreatic Pathol 2004 165 5 1499 1508 (Pubitemid 39435150)
31. Insulin Resistance in Patients with Chronic Hepatitis C Infection. Ade El Satar H, Mahfouz M, Rashed L, Ahmed D, Aust J Basic Appl sci 2010 4 10 4554 4558
32. Hepatitis C Virus Core Protein Upregulates Serine Phosphorylation of Insulin Receptor Substrate-1 and Impairs the Downstream Akt/Protein Kinase B Signaling Pathway for Insulin Resistance. Banerjee S, Saito K, Ait-Goughoulte M, Meyer K, Ray RB, Ray R, J Virol 2008 82 6 2606 2612 10.1128/JVI.01672-07 18160431 (Pubitemid 351329151)
33. Hepatitis C virus induces oxidative stress, DNA damage and modulates the DNA repair enzyme NEIL1. Pal S, Polyak SJ, Bano N, Qiu WC, Carithers RL, Shuhart M, Gretch DR, Das A, J Gastro Hepatol 2010 25 3 327 634
34. Hepatitis C core protein inhibits induction of heme oxygenase-1 and sensitizes hepatocytes to cytotoxicity. Wen F, Brown KE, Britigan BE, Schmidt WN, Cell Biol Toxicol 2008 24 2 175 88 10.1007/s10565-007-9027-9 17721824 (Pubitemid 351311393)
35. Nonstructural 3 protein of hepatitis C virus triggers an oxidative burst in human monocytes via activation of NADPH oxidase. Bureau C, Bernad J, Chaouche N, Orfila C, Béraud M, Gonindard C, Alric L, Vinel JP, Pipy B, J Biol Chem 2001 276 25 23077 83 10.1074/jbc.M100698200 11304537
36. A hepatitis C virus-encoded, nonstructural protein (NS3) triggers dysfunction and apoptosis in lymphocytes: role of NADPH oxidase-derived oxygen radicals. Thoren F, Romero A, Lindh M, Dahlgren C, Hellstrand K, J Leukoc Biol 2004 76 6 1180 6 10.1189/jlb.0704387 15371490 (Pubitemid 39602954)
37. Role of hepatitis C virus proteins (C, NS3, NS5A) in hepatic oncogenesis. Kasprzak A, Adamek A, Hepatol Res 2008 38 1 1 26 10.1111/j.1872-034X.2007. 00261.x 17894800 (Pubitemid 350182573)
38. Hepatitis C virus subgenomic replicons induce endoplasmic reticulum stress activating an intracellular signaling pathway. Tardif KD, Mori K, Siddiqui A, J Virol 2002 76 15 7453 9 10.1128/JVI.76.15.7453-7459.2002 12097557 (Pubitemid 34760967)
39. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Gong G, Waris G, Tanveer R, Siddiqui A, Proc Natl Acad Sci 2001 98 17 9599 604 10.1073/pnas.171311298 11481452 (Pubitemid 32769349)
40. Activation of endoplasmic reticulum stress response by hepatitis viruses up-regulates protein phosphatase 2A. Christen V, Treves S, Duong FH, Heim MH, Hepatol 2007 46 2 558 65 10.1002/hep.21611 (Pubitemid 47344792)
41. The protein phosphatase 2A represents a novel cellular target for hepatitis C virus NS5A protein. Georgopoulou U, Tsitoura P, Kalamvoki M, Mavromara P, Biochimie 2006 88 6 651 62 10.1016/j.biochi.2005.12.003 16460864 (Pubitemid 44081829)
42. Virus-induced over-expression of protein phosphatase 2A inhibits insulin signalling in chronic hepatitis C. Bernsmeier C, Duong FH, Christen V, Pugnale P, Negro F, Terracciano L, Heim MH, J Hepatol 2008 49 3 429 40 10.1016/j.jhep.2008.04.007 18486982
43. Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. Duong FH, Filipowicz M, Tripodi M, La Monica N, Heim MH, Gastroenterol 2004 126 263 277 10.1053/j.gastro.2003.10.076 (Pubitemid 38040741)
44. Non-structural 5A protein of hepatitis C virus induces a range of liver pathology in transgenic mice. Wang AG, Lee DS, Moon HB, Kim JM, Cho KH, Choi SH, Ha HL, Han YH, Kim DG, Hwang SB, Yu DY, J Pathol 2009 219 2 253 62 10.1002/path.2592 19621337
45. Hepatitis C virus infection: molecular pathways to metabolic syndrome. Sheikh MY, Choi J, Qadri I, Friedman JE, Sanyal AJ, Hepatol 2008 47 6 2127 33 10.1002/hep.22269 (Pubitemid 351945577)
46. The role of TNFalpha and TNF receptors in obesity and insulin resistance. Hotamisligil GS, J Intern Med 1999 245 6 621 5 10.1046/j.1365-2796.1999.00490.x 10395191 (Pubitemid 29278870)
47. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Pazienza V, Clement S, Pugnale P, Conzelman S, Foti M, Mangia A, Negro F, Hepat 2007 45 5 1164 71 10.1002/hep.21634 (Pubitemid 46775778)
48. Rapamycin-sensitive pathway downregulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Haruta T, Uno T, Kawahara J, Takano A, Egawa K, Sharma PM, Olefsky JM, Kobayashi MA, Mol Endocrinol 2000 14 783 794 10.1210/me.14.6.783 10847581 (Pubitemid 32260492)
49. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. Rui L, Yuan M, Frantz D, Shoelson S, White MF, J Biol Chem 2002 277 42394 42398 10.1074/jbc.C200444200 12228220 (Pubitemid 35257562)
50. A mathematical model of metabolic insulin signaling pathways. Sedaghat AR, Sherman A, Quon MJ, Am J Physiol Endocrinol Metabol 2002 283 5 1084 101
51. Function and dysfunction of a PKC isoforms for glucose transport in insulin-sensitive and insulin-resistant states. Farese RV, Am J Physiol Endocrinol Metab 2002 283 1 E11 12067836
52. Hepatitis C virus (HCV) associated steatosis and increased gluconeogenic gene expression in Huh8 cells: essential role of NS5A and C/EBP Choudhury M, Qadri I, Rahman M, Knotts TA, Janssen RC, Iwahashi M, Puljak L, Simon FR, Kilic G, Fitz GJ, Friedman JE, FASEB J 2010 24 1b 115
53. Lipotoxic diseases of nonadipose tissues in obesity. Unger RH, Orci L, Intern J Obesity 2000 24 4 28 S32
54. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. Perlemuter G, Sabile A, Letteron P, Vona G, Topilco A, Chrétien Y, Koike K, Pessayre D, Chapman J, Barba G, Bréchot C, FASEB J 2002 16 2 185 94 10.1096/fj.01-0396com 11818366 (Pubitemid 34113012)
55. Regulation of microsomal triglyceride transfer protein gene by insulin in HepG2 cells: roles of MAPK erk and MAPKp38. Au WS, Kung HF, Lin MC, Diabetes 2003 52 1073 1080 10.2337/diabetes.52.5.1073 12716735 (Pubitemid 36523339)
56. Enhanced hepatitis C virus genome replication and lipid accumulation mediated by inhibition of AMP-activated protein kinase. Mankouria J, Tedburya PR, Grettona S, Hughesa ME, Griffina SD, Dallas ML, Green KA, D Hardie G, Peers C, Harris M, PNAS 2010 107 25 11549 54 10.1073/pnas.0912426107 20534540
57. HCV core protein induces hepatic lipid accumulation by activating SREBP1 and PPAR gamma. Kim KH, Hong SP, Kim K, Park MJ, Kim KJ, Cheong J, Biochem Biophy Res Commun 2007 355 4 883 8 10.1016/j.bbrc.2007.02.044 (Pubitemid 46366910)